Aminoterminal propeptide of type I procollagen (PINP) correlates to bone loss and predicts the efficacy of antiresorptive therapy in pre- and post-menopausal non-metastatic breast cancer patients
1998

PINP and Bone Loss in Breast Cancer Patients

Sample size: 206 publication Evidence: high

Author Information

Author(s): T Saartol, C Blomqvist, J Risteli, L Risteli, S Sarna, I Elomaa

Primary Institution: Department of Oncology, University of Helsinki

Hypothesis

The study aims to determine the correlation between changes in collagen metabolites and bone mineral density in breast cancer patients.

Conclusion

Changes in PINP levels significantly predicted changes in bone mineral density and correlated with the efficacy of clodronate treatment.

Supporting Evidence

  • PINP levels at 12 months were significantly lower in the clodronate group than in the control group.
  • There was a highly significant negative correlation between the changes in PINP and BMD.
  • Changes in PINP levels significantly predicted changes in BMD at 24 months.
  • Baseline PINP level was significantly higher in post-menopausal than in premenopausal patients.
  • Clodronate treatment significantly improved BMD in post-menopausal patients.

Takeaway

This study found that a specific protein level can help predict how much bone women with breast cancer will lose, especially after menopause.

Methodology

The study measured bone mineral density and collagen metabolites in breast cancer patients receiving adjuvant therapy and clodronate.

Limitations

The study excluded patients with bone metastases and those with missing laboratory values.

Participant Demographics

206 pre- and post-menopausal women with operable breast cancer.

Statistical Information

P-Value

P < 0.0001

Confidence Interval

(-0.75, -0.60)

Statistical Significance

p<0.0001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication